Last updated: February 15, 2026
What Is NDC 67877-0659?
NDC 67877-0659 corresponds to Nivolumab (Opdivo), a PD-1 immune checkpoint inhibitor manufactured by Bristol-Myers Squibb. It is approved for multiple cancers, including melanoma, NSCLC, renal cell carcinoma, and others.
Market Size and Demand Dynamics
Current Market Scope
- Global Immunotherapy Market Size (2022): approximately $75 billion.
- Nivolumab's share (estimated): 25% of PD-1/PD-L1 inhibitors.
- U.S. market (2022): Estimated revenue of $6.8 billion for nivolumab variants[1].
Approved Indications and Usage Volume
- Oncology indications: Melanoma, NSCLC, renal cell carcinoma, Hodgkin's lymphoma.
- Prescriptions (2022): Roughly 1.5 million yearly U.S. prescriptions.
- Expansion: Clinical trials expanded into gastric, bladder, and cervical cancers.
Competitive Landscape
- Primary competitors: Pembrolizumab (Keytruda), Atezolizumab (Tecentriq), Durvalumab (Imfinzi).
- Market share (2022): Nivolumab holds approximately 50% of the PD-1 inhibitor market in the U.S., trailing behind Keytruda at ~60%[2].
Pricing Structure and Revenue Streams
List Price
- U.S.: Approximate wholesale acquisition cost (WAC) for nivolumab: $5,300 per 40 mg vial, $9,850 per 100 mg vial (2022).
- Typical doses: 240 mg biweekly for melanoma or NSCLC, leading to approximate treatment costs of $12,720 per infusion.
Pricing Trends
- Price Inflation: Minor increase (~1-3%) annually over previous five years.
- Biosimilar Impact: No approved biosimilars for nivolumab as of 2023; potential market entrance could lead to price reductions in 2026+.
Reimbursement Dynamics
- Payer coverage: Broad coverage with prior authorization due to high-cost nature.
- Cost-effectiveness: Cost per quality-adjusted life year (QALY) varies by indication, generally ranging from $100,000 to $200,000.
Future Market Projections
Revenue Forecasts (2023–2030)
| Year |
Estimated Revenue (USD billions) |
Key Drivers |
| 2023 |
7.2 |
Stable demand, expansion into new indications |
| 2025 |
9.0 |
Launch of new indications, combination therapies |
| 2030 |
12.0 |
Increased adoption, potential price tiers in biosimilars |
Factors Influencing Price and Market Penetration
- Patent Status: Expiring in 2028 for some formulations; biotech entrants could influence pricing.
- Regulatory Approvals: New indications approved, expanding market size.
- Market Competition: Keytruda’s market share growth could pressure nivolumab prices.
- Biosimilars: Pending biosimilar approvals could decrease prices by 15–30% starting 2026, affecting revenue margins.
Regulatory and Policy Landscape
- Pricing Policies: U.S. inflation rebates and Medicare negotiations under the Inflation Reduction Act (2022) may influence drug prices.
- Global Access: Price controls in Europe and emerging markets could limit profit margins.
Strategic Recommendations
- Monitor biosimilar developments closely; delays or approvals will impact pricing.
- Explore expansion into CNS and pediatric oncology to maintain revenue growth.
- Engage in value-based contracting with payers to stabilize revenue streams.
Key Takeaways
- Nivolumab (NDC 67877-0659) remains a leading PD-1 inhibitor with a dominant share in the immunotherapy market.
- Current U.S. list prices per infusion are approximately $12,720, with minor annual increases.
- Revenue projections suggest growth to $12 billion by 2030, driven by new indications and expanded use.
- Biosimilar entry expected after 2026 could reduce prices significantly, impacting profit margins.
- Market dynamics are influenced by patent expiration, regulatory policies, and competitors' strategies.
FAQs
1. When will biosimilars for nivolumab become available, and how will they impact pricing?
Biosimilars are expected to be approved from 2026 onward, potentially reducing nivolumab prices by 15–30%. Their entry will increase price competition and market share redistribution.
2. What are the main indications that drive nivolumab's revenue?
Current primary indications include melanoma, non-small cell lung cancer, renal cell carcinoma, and Hodgkin's lymphoma. Ongoing trials aim to expand into gastric, bladder, and cervical cancers.
3. How does the pricing of nivolumab compare to similar therapies?
Nivolumab's list price per infusion (~$12,720) aligns with pembrolizumab but exceeds some other checkpoint inhibitors, reflecting its market position and clinical efficacy profile.
4. How might regulatory changes or policy shifts affect nivolumab's market?
Medicare negotiation power and drug price controls under recent legislation may pressure prices downward. Payer policies also influence reimbursement rates and access.
5. What are the key risks to revenue growth for nivolumab?
Risks include biosimilar competition, market saturation, changing payer policies, and possible safety concerns leading to formulary restrictions.
References
- IQVIA Institute. (2022). "The Global Oncology Market."
- EvaluatePharma. (2022). "Top 10 Oncology Drugs by Revenue."
